Cargando…

META-ANALYSIS OF CYP2D6 METABOLIZER PHENOTYPE AND METOPROLOL PHARMACOKINETICS

Metoprolol, a commonly prescribed beta-blocker, is primarily metabolized by cytochrome P450 2D6 (CYP2D6), an enzyme with substantial genetic heterogeneity. Several smaller studies have shown that metoprolol pharmacokinetics is influenced by CYP2D6 genotype and metabolizer phenotype. To increase robu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blake, CM, Kharasch, ED, Schwab, M, Nagele, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818912/ https://www.ncbi.nlm.nih.gov/pubmed/23665868 http://dx.doi.org/10.1038/clpt.2013.96

Ejemplares similares

Effects of Flos carthami on CYP2D6 and on the Pharmacokinetics of Metoprolol in Rats
por: Liu, Gaofeng, et al.
Publicado: (2011)

Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug
por: Berger, Benjamin, et al.
Publicado: (2018)

Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions
por: Rüdesheim, Simeon, et al.
Publicado: (2020)

Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype‐Derived Activity Scores
por: Thomas, Cameron D., et al.
Publicado: (2020)

Impact of CYP2D6 polymorphisms on clinical efficacy & tolerability of metoprolol tartrate
por: Hamadeh, Issam S., et al.
Publicado: (2014)

Effect of Naoxintong Capsules on the Activities of CYP450 and Metabolism of Metoprolol Tartrate in Rats Evaluated by Probe Cocktail and Pharmacokinetic Methods
por: Ouyang, Huizi, et al.
Publicado: (2019)

The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis
por: Tran, Quyen Thi, et al.
Publicado: (2022)

Metoprolol and CYP2D6: A Retrospective Cohort Study Evaluating Genotype-Based Outcomes
por: Collett, Savannah, et al.
Publicado: (2023)

Pharmacokinetic Interaction between Pyronaridine-Artesunate and Metoprolol
por: Morris, Carrie A., et al.
Publicado: (2014)

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
por: Grzegorzewski, Jan, et al.
Publicado: (2022)

Impact of the CYP2D6 Genotype on Metoprolol Tolerance and Adverse Events in Elderly Chinese Patients With Cardiovascular Diseases
por: Chen, Jianqiao, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone
por: Rüdesheim, Simeon, et al.
Publicado: (2022)

The impact of CYP2D6 mediated drug–drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine
por: Bahar, Muh. Akbar, et al.
Publicado: (2018)

Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway
por: Gedde-Dahl, Ane, et al.
Publicado: (2022)

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach
por: Kneller, Lisa Alina, et al.
Publicado: (2021)

Effect of Water-miscible Organic Solvents on CYP450-mediated Metoprolol and Imipramine Metabolism in Rat Liver Microsomes
por: Shah, T. S., et al.
Publicado: (2015)

Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers
por: Chung, Woo Kyung, et al.
Publicado: (2022)

Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes
por: Bloom, Adam Joseph, et al.
Publicado: (2019)

Physiologically‐based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups
por: Rüdesheim, Simeon, et al.
Publicado: (2022)

Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine
por: Frederiksen, Trine, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Model To Predict Metoprolol Disposition in Healthy and Disease Populations
por: Zamir, Ammara, et al.
Publicado: (2023)

CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry
por: Molden, Espen, et al.
Publicado: (2021)

Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model
por: Marsousi, N, et al.
Publicado: (2014)

Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6
por: Lee, Joomi, et al.
Publicado: (2019)

Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach
por: Kneller, Lisa Alina, et al.
Publicado: (2020)

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype
por: Haage, Pernilla, et al.
Publicado: (2018)

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies
por: Li, Danyang, et al.
Publicado: (2023)

Impact of amiodarone use on metoprolol concentrations, α‐OH‐metoprolol concentrations, metoprolol dosing and heart rate: A cross‐sectional study
por: Robert, Sabrina, et al.
Publicado: (2023)

Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6‐Mediated Metabolic Activity
por: Dalton, Rachel, et al.
Publicado: (2019)

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes
por: Kim, Se-Hyung, et al.
Publicado: (2018)

CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6(∗)10 on Interindividual Variation in a Chinese Population
por: Chen, Rui, et al.
Publicado: (2017)

Gender Dependency in Streoselective Pharmacokinetics of Tramadol and Its Phase I Metabolites in Relation to CYP2D6 Phenotype in Iranian Population
por: Hosseinzadeh Ardakani, Yalda, et al.
Publicado: (2018)

Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network
por: Feick, Denise, et al.
Publicado: (2023)

Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients
por: Chan, Sze Wa, et al.
Publicado: (2021)

Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population
por: Friedrich, Deise C., et al.
Publicado: (2014)

The impact of CYP2D6*41 on CYP2D6 enzyme activity using phenotyping methods in urine, plasma, and saliva
por: Jin, Ye, et al.
Publicado: (2022)

Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19
por: Koopmans, Anne B., et al.
Publicado: (2021)

Health expenditure comparison of extended-release metoprolol succinate and immediate-release metoprolol tartarate
por: Vaidya, Varun, et al.
Publicado: (2012)

Metoprolol Dose Equivalence in Adult Men and Women Based on Gender Differences: Pharmacokinetic Modeling and Simulations
por: Eugene, Andy R.
Publicado: (2016)

Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis
por: Vizeli, Patrick, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ntacekndcit3lj9k05vlfgkl3n